Vaccination with an Attenuated Ferritin Mutant Protects Mice against Virulent Mycobacterium tuberculosis

Journal of Immunology Research
Selvakumar SubbianG Marcela Rodriguez

Abstract

Mycobacterium tuberculosis the causative agent of tuberculosis affects millions of people worldwide. New tools for treatment and prevention of tuberculosis are urgently needed. We previously showed that a ferritin (bfrB) mutant of M. tuberculosis has altered iron homeostasis and increased sensitivity to antibiotics and to microbicidal effectors produced by activated macrophages. Most importantly, M. tuberculosis lacking BfrB is strongly attenuated in mice, especially, during the chronic phase of infection. In this study, we examined whether immunization with a bfrB mutant could confer protection against subsequent infection with virulent M. tuberculosis in a mouse model. The results show that the protection elicited by immunization with the bfrB mutant is comparable to BCG vaccination with respect to reduction of bacterial burden. However, significant distinctions in the disease pathology and host genome-wide lung transcriptome suggest improved containment of Mtb infection in animals vaccinated with the bfrB mutant, compared to BCG. We found that downmodulation of inflammatory response and enhanced fibrosis, compared to BCG vaccination, is associated with the protective response elicited by the bfrB mutant.

References

Sep 7, 2002·The Journal of Biological Chemistry·John S WelchChristopher K Glass
Oct 22, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Siobhán C Cowley, Karen L Elkins
Aug 3, 2004·Nature Reviews. Immunology·Thomas A Wynn
May 10, 2006·Proceedings of the National Academy of Sciences of the United States of America·Meenakshi AroraPrabir Ray
Jun 9, 2006·Trends in Microbiology·G Marcela Rodriguez
Jul 20, 2007·The Journal of Biological Chemistry·Irina TreedeRobert Ehehalt
Dec 7, 2007·Scandinavian Journal of Immunology·J-S LeeE-K Jo
Jan 24, 2009·Immunological Reviews·Andrea M Cooper, Shabaana A Khader
Mar 24, 2009·Annual Review of Immunology·Andrea M Cooper
Feb 18, 2010·Antimicrobial Agents and Chemotherapy·Diane J OrdwayIan M Orme
Oct 22, 2010·The Pediatric Infectious Disease Journal·Diana AverbuchDan Engelhard
Aug 2, 2011·Cytokine & Growth Factor Reviews·Mingli LiuJonathan K Stiles
Aug 2, 2011·European Journal of Immunology·Gillian S TomlinsonMahdad Noursadeghi
Jan 28, 2012·Cell Communication and Signaling : CCS·Mi-Sun KooGilla Kaplan
May 1, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sahil MahajanPawan Gupta
Feb 12, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Joshua C CyktorJoanne Turner
Mar 23, 2013·Annual Review of Immunology·Kong Chen, Jay K Kolls
Aug 21, 2013·Cell Communication and Signaling : CCS·Selvakumar SubbianGilla Kaplan
Jan 15, 2014·Journal of Bacteriology·Rafael Prados-RosalesG Marcela Rodriguez

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

Mx4000
Affymetrix Command Console
Partek Genomics Suite
IPA
Affymetrix
Sigmascan Pro
Systat

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
Prasanta Raghab Mohapatra, Ashok Kumar Janmeja
© 2021 Meta ULC. All rights reserved